论文部分内容阅读
[目的]探讨消化系统恶性肿瘤患者血清中癌胚抗原(CEA)、癌抗原19-9(CA19-9)、癌抗原242(CA242)水平的变化及联合检测的临床意义。[方法]应用化学发光法和酶联免疫法测定178例消化系统恶性肿瘤患者(肿瘤组)血清中CEA、CA19-9、CA242水平,并与204例消化系统良性疾病(对照组)作比较。[结果]肿瘤组血清CEA、CA19-9、CA242水平显著高于对照组(P<0.05),3项联合检测可提高肝癌、胃癌、胰腺癌、结直肠癌的特异性(P<0.05),敏感性未见增加。[结论]联合检测消化系统恶性肿瘤患者血清CEA、CA19-9、CA242水平,对临床诊断和疗效观察具有重要的价值。
[Objective] To investigate the changes of serum carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9) and cancer antigen 242 (CA242) in patients with digestive system malignant tumor and the clinical significance of combined detection. [Method] The serum levels of CEA, CA19-9 and CA242 in 178 patients with digestive system malignancy (tumor) were determined by chemiluminescence and enzyme-linked immunosorbent assay (ELISA), and compared with 204 cases of benign digestive diseases (control group). [Results] The serum levels of CEA, CA19-9 and CA242 in the tumor group were significantly higher than those in the control group (P <0.05). The three combined tests could improve the specificity of liver cancer, gastric cancer, pancreatic cancer and colorectal cancer (P <0.05) No increase in sensitivity. [Conclusion] The combined detection of serum CEA, CA19-9 and CA242 levels in patients with digestive system malignancies is of great value in clinical diagnosis and treatment.